- Recursion ( NASDAQ: RXRX ) on Thursday said the European Commission had granted an orphan drug designation to its inhibitor REC-4881 for the treatment of familial adenomatous polyposis (FAP).
- FAP is an inherited disorder characterized by the formation of growths called polyps in the colon. If not recognized or treated in time, there is a high likelihood of the growths becoming cancerous.
- The European Medicines Agency's orphan designation is given to medicines developed for rare, life-threatening diseases.
- The U.S. FDA in Sept. last year had granted RXRX an orphan drug designation for REC-4881.
- RXRX stock closed 1.6% higher at $8.99 on Wednesday.
For further details see:
Recursion gets European orphan drug designation for its REC-4881 inhibitor